Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Source: 
TheStreet.com
snippet: 

Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.